>

Regeneron Stock Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

USD 452.66  27.28  6.41%

The latest increase in of Regeneron Pharmaceuticals short term price appreciation has created some momentum for investors as it was traded today as low as 452.66 and as high as 479.94 per share. The company directors and management have been quite successful with maneuvering the fund at opportune times to take advantage of all market conditions in January. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.98. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. The Regeneron Pharmaceuticals financial analysis interface makes it easy to digest most current publicly released information about Regeneron Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Regeneron stock analysis module also helps to analyze Regeneron Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency. Additionally, take a look at Your Equity Center.
Equity
Refresh

Regeneron Stock Analysis Notes

About 25.0% of the company outstanding shares are owned by corporate insiders. The book value of Regeneron Pharmaceuticals was at this time reported as 41.1. The company has Price/Earnings To Growth (PEG) ratio of 1.75. Regeneron Pharmaceuticals recorded earning per share (EPS) of 18.69. The entity had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 8100 people. To find out more about REGENERON PHARMAC contact Leonard Schleifer at 914 847-7000 or learn more at www.regeneron.com.

Regeneron Pharmaceuticals Investment Alerts

About 71.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Exercise or conversion by Robert Landry of 2000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals Upcoming and Recent Events

Upcoming Quarterly Earning ReportMay 5, 2020
Next Earnings ReportAugust 4, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 4, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Regeneron Pharmaceuticals Earning Estimates

EPSEstimate Date
Quarterly Estimate5.91May 5, 2020
Regeneron Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Regeneron Pharmaceuticals SEC Filings

Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Unclassified Corporate Event. Results of Operations and Financial Condition
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
Entry into a Material Definitive Agreement

Regeneron Pharmaceuticals Thematic Classifications

Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 40.53 B.

Profitablity

The company has Profit Margin (PM) of 29.03 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 32.16 % which suggests for every 100 dollars of sales it generated a net operating income of 0.32.

Management Efficiency

Regeneron Pharmaceuticals has return on total asset (ROA) of 13.61 % which means that it generated profit of $13.61 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.87 % meaning that it created $18.87 on every $100 dollars invested by stockholders.

Institutional Stock Holders for Regeneron Pharmaceuticals

Information
Ratio
Value
At Risk
DWS CROCI U S Fund Class R6(0.1) (1.43) 
Chautauqua Global Growth Fund(0.0019) (1.45) 
NASDAQ 100 Notional Net Total R 0.0485 (2.79) 
NASDAQ 100 Total Return Index 0.0124 (2.85) 
NASDAQ Biotechnology Total Retu(0.0176) (2.79) 
NASDAQ 100 Pre Market Indicator 0.0373 (1.54) 
NASDAQ 100 After Hours Indicato 0.0485 (2.47) 
Nasdaq Yewno Global Innovative 0.0131 (1.53) 
NASDAQ 100 Reduced Value Index 0.0469 (2.80) 
Nasdaq Victory US 500 Large Vol(0.0151) (1.89) 
Nasdaq Victory US 500 Large Vol(0.019) (1.89) 
Nasdaq Victory US 500 Large Vol(0.019) (1.89) 
Nasdaq US Large Cap Growth NTR 0.0444 (2.07) 
NASDAQ US Large Mid Cap Index(0.0009) (1.82) 
Nasdaq US Sustainable Momentum 0.0028 (1.52) 
NASDAQ N America Large Mid Cap(0.0002) (1.79) 
NASDAQ Global Select Market Com 0.05 (1.84) 
Nasdaq Dorsey Wright Peoples Po(0.0044) (1.96) 
Nasdaq CRD Global Sustainabilit 0.0204 (1.33) 
Nasdaq CRD Global Sustainabilit 0.0088 (1.55) 

Technical Drivers

As of the 25th of February Regeneron Pharmaceuticals holds Risk Adjusted Performance of 0.1719, Semi Deviation of 1.31 and Coefficient Of Variation of 540.32. Compared with Fundamental Indicators, Macroaxis technical analysis interface allows you to check existing technical drivers of Regeneron Pharmaceuticals as well as the relationship between them. Put it differently you can use this information to find out if the company will indeed mirror its model of past market data or the prices will eventually revert. We found nineteen technical drivers for Regeneron Pharmaceuticals, which can be compared to its competitors. Please check Regeneron Pharmaceuticals Downside Deviation, Jensen Alpha as well as the relationship between Jensen Alpha and Downside Variance to decide if Regeneron Pharmaceuticals is priced some-what accurately providing market reflects its current price of 452.66 per share. Given that Regeneron Pharmaceuticals has Jensen Alpha of 0.3259, we recommend you check out Regeneron Pharmaceuticals recent market performance to make sure the company can sustain itself at future point.

Regeneron Pharmaceuticals Price Movement Analysis

The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Regeneron Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Regeneron Pharmaceuticals Insider Trading Activities

Sanofi 2 days ago via Macroaxis 
Purchase by Sanofi of 265 shares of Regeneron Pharmaceuticals
Leonard Schleifer 3 days ago via Macroaxis 
Payment of 6257 shares by Leonard Schleifer of Regeneron Pharmaceuticals subject to Rule 16b-3
Robert Landry few days ago via Macroaxis 
Exercise or conversion by Robert Landry of 2000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Sanofi six days ago via Macroaxis 
Purchase by Sanofi of 18945 shares of Regeneron Pharmaceuticals
Roberts William over a week ago via Macroaxis 
Exercise or conversion by Roberts William of 1685 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Shooter Eric M over a week ago via Macroaxis 
Exercise or conversion by Shooter Eric M of 1572 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Robert Landry over a week ago via Macroaxis 
Exercise or conversion by Robert Landry of 500 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Neil Stahl over a week ago via Macroaxis 
Sale by Neil Stahl of 4302 shares of Regeneron Pharmaceuticals
Leonard Schleifer over a week ago via Macroaxis 
Sale by Leonard Schleifer of 450 shares of Regeneron Pharmaceuticals
Michael Brown over two weeks ago via Macroaxis 
Sale by Michael Brown of 400 shares of Regeneron Pharmaceuticals
George Yancopoulos over two weeks ago via Macroaxis 
Exercise or conversion by George Yancopoulos of 456 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Vagelos P Roy over two weeks ago via Macroaxis 
Regeneron Pharmaceuticals exotic insider transaction detected

Regeneron Pharmaceuticals Predictive Indicators

Regeneron Pharmaceuticals Forecast Models

Recommendations

Regeneron Pharmaceuticals Analyst Recommendations

Target PriceAdvice# of Analysts
404.82Hold17Odds
Regeneron Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Regeneron Pharmaceuticals Analyst Advice  

Vital Value Indicators

Regeneron Pharmaceuticals Basic Pricing Drivers

Quick Ratio2.82
Fifty Two Week Low271.37
Revenue Growth12.50%
Shares Short Prior Month2.48M
Average Daily Volume Last 10 Day597.65k
Average Daily Volume In Three Month778.62k
Earnings Growth-3.10%
Shares Percent Shares Out2.63%
Gross Margins51.44%
Earnings Quarterly Growth-3.50%
Short Percent Of Float3.62%
Forward Price Earnings14.02
Float Shares80.89M
Fifty Two Week High442.00
Enterprise Value To Ebitda16.86
Fifty Day Average374.91
Two Hundred Day Average333.33
Enterprise Value To Revenue5.27
Additionally, take a look at Your Equity Center. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Company logos by clearbit